Prostate Cancer VA Rating

Prostate cancer at the BVA looks different from most conditions. Across 7,485 decided Board rulings on prostate cancer from 2021 to 2026, the grant rate is 32.3 percent, 7.6 points above the Board-wide 24.7 percent. A ruling is one issue the Board decided in one decision; one decision often rules on several issues. Presumptions are a large part of the picture: most of the Board's service connection rulings on prostate cancer involved a presumption of service connection, and those claims were granted a little more often than direct claims. Camp Lejeune still deserves a flag, because prostate cancer is not on the Camp Lejeune presumptive list.

In my read, the reason for the grant rate isn't that prostate cancer is medically easier to prove. It's that the regulation does the work the veteran would otherwise have to do. The Agent Orange presumption removes the nexus question for a veteran with qualifying herbicide-exposure service, such as service in Vietnam or its offshore waters. The PACT Act presumption does the same for veterans with covered Gulf War or post-9/11 service in the locations listed in 38 USC § 1119(c). Once service connection is established, the rating starts at 100 percent during active treatment under DC 7528.

What veterans don't always realize is that the 100 percent rating doesn't last forever. Six months after the last day of active treatment, VA is required to re-examine you. If the cancer has not come back or spread, the rating then depends on the residuals: voiding dysfunction (leakage, frequency or obstructed voiding) or renal dysfunction under DC 7528, with erectile dysfunction rated separately. That re-evaluation is where many prostate cancer rating disputes start.

This page covers the DC 7528 rating criteria, Agent Orange and the PACT Act, the residual ratings for leakage, frequency and erectile dysfunction, how to prove a prostate cancer claim, and why VA denies prostate cancer claims.

TL;DR

• Across 7,485 decided Board rulings on prostate cancer from 2021 to 2026, 32.3% were granted, 30.9% denied and 36.8% remanded. Remand is still the most common outcome, but the grant rate is 7.6 points above the Board-wide 24.7%.
• Claims argued under a presumption were granted a little more often than direct claims, and secondary claims less often than either. The Board section below shows all three.
• The presumptions that apply are Agent Orange and the PACT Act. Prostate cancer is not on the Camp Lejeune presumptive list, and radiation claims go through the dose review in 38 CFR § 3.311 rather than a presumption.
• DC 7528 rates malignant neoplasms of the genitourinary system at 100 percent during treatment, and the 100 percent continues after treatment ends until a mandatory VA exam six months later. If there is no recurrence or spread, VA then rates the residuals, and any reduction has to follow the notice rules in 38 CFR § 3.105(e).
• Voiding dysfunction tops out at 60 percent, so a 100 percent rating reflects active treatment and the period until the six-month exam, recurrence or metastasis, or renal dysfunction at the 100 percent level.
• Among service connection rulings the Board granted or denied, those where it weighed no medical opinion were granted more often than the prostate cancer average, which fits how a presumption can carry a claim without one. The Board section below shows what the Board did with medical opinions.
• Appeals over the rating itself were granted less often than service connection appeals. Many are residuals-stage appeals, where the fight is whether the voiding documentation supports a higher tier or whether SMC(k) applies. The Board section below shows results by what the appeal asked for.

Prostate cancer VA rating criteria (DC 7528)

Prostate cancer is rated under DC 7528, "Malignant neoplasms of the genitourinary system," in the genitourinary chapter at 38 CFR § 4.115b.

The rating mechanics are unusual. Most diagnostic codes describe a tier ladder based on severity of symptoms. DC 7528 instead describes a temporal sequence: a 100 percent rating during the active treatment phase, a mandatory VA examination six months after treatment ends, and then a residuals-based rating if the cancer has not come back or spread.

The full regulatory text reads as follows.

"Malignant neoplasms of the genitourinary system: 100. Note: Following the cessation of surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure, the rating of 100 percent shall continue with a mandatory VA examination at the expiration of six months. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter. If there has been no local reoccurrence or metastasis, rate on residuals as voiding dysfunction or renal dysfunction, whichever is predominant."

Three structural features matter here.

The 100 percent rating during active treatment is automatic. While the cancer is active and while you are in surgery, radiation, chemotherapy or another therapeutic procedure for it, the rating is 100 percent. There's no severity threshold to clear. The diagnosis plus active treatment plus service connection equals 100 percent. If you are on hormone therapy, the oncologist's records should say what it is for and whether it is still running.

The six-month examination is mandatory. VA is required by regulation to schedule a re-examination six months after the last day of active treatment. The note ties any change in the rating to that examination or a later one, so the 100 percent rating continues until VA actually re-examines you. Any reduction is also subject to § 3.105(e): VA has to propose it in writing, explain why, and give you 60 days to send evidence before it takes effect. This is a procedural protection veterans don't always know about: VA bears the burden of moving the case forward.

The residuals rating is based on what's left after treatment. Prostate cancer treatment commonly leaves urinary leakage, urinary frequency and erectile dysfunction, and some treatments leave bowel problems. In one French cohort of 434 men followed five years after diagnosis, more than half reported urinary incontinence and more than half reported erectile dysfunction. DC 7528 rates the predominant voiding or renal dysfunction; erectile dysfunction is rated separately under DC 7522.

Agent Orange and prostate cancer

Agent Orange is the longest-standing presumption for prostate cancer. Under 38 USC § 1116, VA's herbicide list in 38 CFR § 3.309(e) includes prostate cancer, and § 3.307(a)(6) lets it appear at any time after service, with no deadline.

Covered herbicide service includes the following.

• Service in the Republic of Vietnam from January 9, 1962 to May 7, 1975, including its offshore waters.
• Service at any U.S. or Royal Thai base in Thailand from January 9, 1962 to June 30, 1976, wherever on the base you worked.
• Service in Laos from December 1, 1965 to September 30, 1969.
• Service in Cambodia at Mimot or Krek, Kampong Cham Province, from April 16 to April 30, 1969.
• Service on Guam or American Samoa or in their territorial waters from January 9, 1962 to July 31, 1980, or on Johnston Atoll or a ship that called there from January 1, 1972 to September 30, 1977.
• Service from April 1, 1968 to August 31, 1971 in a unit the Department of Defense found operated in or near the Korean DMZ where herbicides were applied.
• Air Force or Air Force Reserve duty that regularly and repeatedly put you on C-123 aircraft used to spray herbicides.

The qualifying service definition has been expanded several times. The Blue Water Navy Vietnam Veterans Act of 2019 wrote the offshore rule into the statute, 38 USC § 1116A, effective January 1, 2020. It covers service offshore of Vietnam within 12 nautical miles of a line the statute defines. If you served offshore, filed a prostate cancer claim between September 25, 1985 and January 1, 2020 that was denied because service connection was not shown, and file again, the law sets the effective date of a new grant from the date of the earlier claim.

The PACT Act added a burn-pit presumption in 2022. The statute, 38 USC § 1120, lists reproductive cancer of any type, which includes prostate cancer. For veterans with covered Gulf War service (on or after August 2, 1990) or post-9/11 service (on or after September 11, 2001) in the locations listed in 38 USC § 1119(c), prostate cancer is now presumptive on the burn-pit basis.

Camp Lejeune is different. The Camp Lejeune presumptive list in 38 CFR § 3.309(f) does not include prostate cancer, so Camp Lejeune claims need direct evidence linking the cancer to the contaminated water. Radiation exposure is not a presumption either: prostate cancer is not on the radiation presumptive list in § 3.309(d), but it is a listed radiogenic disease under 38 CFR § 3.311, which sends the claim through a radiation dose assessment and review.

The effect of these presumptions is that many prostate cancer claims at the BVA are decided on whether the veteran's service fits one of them, not on whether the cancer is related to military service. Claims argued under a presumption were granted a little more often than direct claims; the Board section below shows both. The presumption settles the link to service, but the Board still has to confirm the diagnosis, the qualifying service and the rating. You can check other presumptive conditions with the presumptive conditions tool.

Prostate cancer residual ratings after the six-month exam

For many veterans, the hardest part of a prostate cancer claim isn't the initial grant. It's the six-month re-evaluation. The 100 percent rating during active treatment is structurally clean. The residuals rating that comes after is where the rating math gets complicated.

The current Board read doesn't code assigned rating tiers, so I can't show where granted cases landed. It does show that appeals over the rating itself were granted less often than service connection appeals; the Board section below shows results by what the appeal asked for. Once service connection is settled, the residuals rating is the harder fight.

A 100 percent rating cannot come from voiding dysfunction, which tops out at 60 percent. It reflects the active-treatment period and the time until the six-month exam, local recurrence or metastasis that keeps or restores the 100 percent rating, or renal dysfunction severe enough for the 100 percent level.

The residuals-based rating depends on which problem is predominant. DC 7528 points to voiding dysfunction or renal dysfunction under 38 CFR § 4.115a, and § 4.115a rates voiding dysfunction as urine leakage, urinary frequency or obstructed voiding.

Urine leakage (incontinence) runs from 20 percent (absorbent material changed less than twice a day) to 40 percent (two to four times a day) to 60 percent (an appliance, or absorbent material changed more than four times a day). Leakage is a common residual after radical prostatectomy, and its 60 percent top level is higher than anything frequency or obstructed voiding can reach.

Urinary frequency rates from 10 percent (daytime voiding interval between two and three hours, or awakening to void twice per night) to 20 percent (one to two hours, or three to four times a night) to 40 percent (daytime voiding interval less than one hour, or awakening to void five or more times per night). When frequency rather than leakage is the main problem, this is the scale that applies.

Obstructed voiding rates 30 percent for urinary retention requiring intermittent or continuous catheterization, and 10 percent for marked obstructive symptoms with at least one listed finding, such as a post-void residual over 150 cc or a peak flow rate under 10 cc per second.

Renal dysfunction rates from 0 percent to 100 percent based mainly on glomerular filtration rate (GFR) sustained for at least 3 consecutive months in the past 12 months, with regular dialysis or eligibility for a kidney transplant at the 100 percent level. It matters when the record shows reduced kidney function after treatment.

Erectile dysfunction is rated at 0 percent under current DC 7522, with or without penile deformity. The former 20-percent deformity criterion was removed in the 2021 genitourinary rewrite, effective November 14, 2021. When ED is service connected as a prostate-cancer treatment residual, VA should also review possible Special Monthly Compensation under SMC-K (38 USC § 1114(k) and 38 CFR § 3.350). SMC entitlement depends on qualifying service-connected loss or loss of use and should be established from the medical record rather than assumed automatically. The erectile dysfunction guide covers that claim in detail.

Getting a higher prostate cancer residual rating

A common pattern in residuals appeals runs like this. The veteran is service-connected for prostate cancer. The active treatment phase is over. The six-month re-evaluation establishes residuals. The veteran appeals seeking a higher residuals rating than the regional office assigned. The Board reviews the residuals documentation and concludes the symptoms don't clear the next tier's threshold.

For leakage specifically, the rating math turns on the frequency and type of absorbent material use. A veteran changing pads less than twice a day is at 20 percent. Two to four changes a day is 40 percent. More than four changes a day, or use of an appliance, is 60 percent. The gap between those tiers depends on what the treating clinical record actually documents.

The path to a higher residuals rating usually involves the following.

• A bladder diary or symptom journal documenting daily voiding frequency and absorbent material use
• Treatment records from a urologist that describe symptom severity in clinically specific terms
• Documentation of any appliance used for leakage, and what it is
• Records of urinary retention that requires catheterization, which rates under obstructed voiding
• A C&P examination that engages with the specific tier criteria rather than treating the residuals generically

When the documentation supports the higher tier specifically, the rating moves. When it describes the symptoms in general terms, the rating tends to stay where it was assigned.

How to prove a prostate cancer claim

These are the pieces a prostate cancer claim needs.

Documented qualifying service for a presumption. DD-214, personnel records, or unit and ship records showing service in a covered location during a covered period. Service in Vietnam or its offshore waters, at a Thai base, or in the other herbicide locations listed above triggers the Agent Orange presumption. Covered Gulf War or post-9/11 service in the locations listed in 38 USC § 1119(c) triggers the PACT Act burn-pit presumption. Camp Lejeune service does not trigger a presumption for prostate cancer, because the Camp Lejeune list in 38 CFR § 3.309(f) does not include it.

Pathology confirmation. The diagnosis itself needs to be supported by a pathology report: biopsy results, surgical pathology, or radiation oncology documentation. Veterans with elevated PSA but no biopsy-confirmed cancer don't qualify for the DC 7528 rating because the malignant neoplasm criterion isn't met.

Active-treatment documentation. The 100 percent rating requires documentation that the cancer is active or that treatment is ongoing. Surgery records, radiation oncology notes, chemotherapy records, and any hormone therapy with its dates belong in the file. Veterans whose treatment ended years ago, who are now in surveillance only and have no recurrence, don't get the 100 percent rating. They get the residuals rating.

A medical opinion when no presumption applies. For Camp Lejeune, radiation or other direct claims, the claim needs a medical opinion that links the cancer to the in-service exposure and explains why. For ionizing radiation, § 3.311 adds a dose assessment.

A six-month examination that engages with the residuals criteria. When the C&P examiner explicitly addresses voiding frequency, absorbent material use, and erectile function with clinical specificity, the residuals rating tends to be defensible. Generic examinations produce generic ratings.

SMC-K review. For veterans with service-connected erectile dysfunction following prostate-cancer treatment, the decision should address possible SMC-K under 38 USC § 1114(k) and 38 CFR § 3.350. The evidence should establish the qualifying loss or loss of use; public guidance should not promise an automatic award or hard-code a payment amount that changes over time.

Why VA denies prostate cancer claims

Prostate cancer claims do better at the Board than most. Across 7,485 decided Board rulings on prostate cancer from 2021 to 2026, 32.3% were granted, 30.9% denied and 36.8% remanded. That grant rate is 7.6 points above the Board-wide 24.7 percent.

When the Board denies prostate cancer service connection, the most common reason is no link between the cancer and service, and most denials also found no qualifying in-service event or exposure. A missing diagnosis is rarely the problem. The patterns repeat.

Service that does not fit the presumption. The records do not place you in a covered location during a covered period. For Thailand, the PACT Act removed the old question of where on the base you served: service at any U.S. or Royal Thai base from January 9, 1962 to June 30, 1976 counts.

A presumption that does not cover prostate cancer. The claim is argued under the Camp Lejeune or radiation presumption, but prostate cancer is on neither list. Without a medical opinion, and for radiation the § 3.311 dose review, the claim has no route.

A direct claim with no medical opinion. Without a presumption, the record needs an opinion that explains how the in-service exposure caused the cancer. A diagnosis and an exposure history are not enough on their own.

No confirmed cancer. An elevated PSA without a biopsy or surgical pathology does not establish a malignant neoplasm.

Residuals below the next tier. In rating appeals, the leakage or frequency records do not show the pad changes or voiding intervals the next level requires.

When the Board sends a prostate cancer claim back instead of deciding it, the most common reason is records VA still had to get, followed by an inadequate VA exam or opinion. The Board section below shows how often each denial and remand reason came up, and what the Board did with medical opinions.

Questions veterans ask about prostate cancer

Is prostate cancer presumptive for Agent Orange?

Yes. Prostate cancer is on VA's herbicide list in 38 CFR § 3.309(e), so a veteran with covered service, such as in Vietnam or its offshore waters from January 9, 1962 to May 7, 1975 or at a Thai base from January 9, 1962 to June 30, 1976, does not need a medical opinion linking it to service. There is no deadline for when the cancer appears.

What is the VA rating for prostate cancer after treatment?

The 100 percent rating continues after treatment ends until a mandatory VA exam six months later. If the cancer has not come back or spread, VA rates the predominant residual: urine leakage up to 60 percent, urinary frequency up to 40 percent, obstructed voiding up to 30 percent, or kidney dysfunction up to 100 percent. Erectile dysfunction is rated separately at 0 percent, with review for special monthly compensation.

Can I get VA disability for erectile dysfunction secondary to prostate cancer?

Yes. If the cancer or its treatment caused the erectile dysfunction, it can be service connected as secondary to service-connected prostate cancer under 38 CFR § 3.310. It is rated 0 percent under DC 7522, but VA should review special monthly compensation under 38 U.S.C. § 1114(k) for loss of use of a creative organ. That payment is not automatic and depends on the medical evidence.

Is prostate cancer covered by the PACT Act?

Yes, for covered veterans. The PACT Act presumes reproductive cancer of any type, which includes prostate cancer, for veterans who served on or after August 2, 1990 in listed Gulf War locations or on or after September 11, 2001 in listed post-9/11 locations, such as Iraq, Kuwait or Afghanistan.

Is prostate cancer presumptive for Camp Lejeune?

No. The Camp Lejeune list in 38 CFR § 3.309(f) covers kidney, liver and bladder cancer, non-Hodgkin's lymphoma, adult leukemia, multiple myeloma, Parkinson's disease, and aplastic anemia and other myelodysplastic syndromes, but not prostate cancer. A Camp Lejeune prostate cancer claim needs a medical opinion linking it to the contaminated water.

Does the 100 percent rating stop automatically after six months?

No. Six months after treatment ends, VA must examine you, and any reduction has to follow 38 CFR § 3.105(e): a written proposal with reasons and 60 days for you to send evidence. If the exam shows the cancer has come back or spread, the 100 percent rating continues.

Bottom Line

Prostate cancer is rated under 38 CFR § 4.115b DC 7528. The structural framework gives veterans 100 percent during active treatment, and the 100 percent continues until a mandatory exam six months after treatment ends. If the cancer has not come back or spread, VA can then lower the rating, with notice under § 3.105(e), to the residuals level based on voiding dysfunction (leakage, frequency or obstructed voiding) or renal dysfunction. In Claim Raven's read of 7,485 decided Board rulings on prostate cancer, the grant rate is 32.3 percent, and claims argued under a presumption were granted more often than direct or secondary claims. For prostate cancer, the presumptions that apply are Agent Orange and the PACT Act; Camp Lejeune is not a presumptive lane for this cancer, and radiation claims go through § 3.311 review. Voiding dysfunction tops out at 60 percent, so a 100 percent rating reflects active treatment, recurrence, or severe renal dysfunction. A common denial pattern at the residuals stage is a finding that the documentation doesn't clearly support the next-higher tier. For service-connected prostate-cancer residuals that include ED, VA should review possible SMC-K under 38 USC § 1114(k) and 38 CFR § 3.350 based on the evidence of loss or loss of use.

Methodology and Limitations

• Data source: 38 CFR § 4.115b DC 7528 (malignant neoplasms of the genitourinary system) and DC 7522 (erectile dysfunction), 38 CFR § 4.115a (genitourinary residuals rating criteria), 38 CFR § 3.105(e) (reductions), 38 USC § 1116 and 38 CFR §§ 3.307(a)(6) and 3.309(e) (Agent Orange), 38 USC § 1116A (Blue Water Navy), 38 USC §§ 1119 and 1120 (PACT Act burn pit), 38 CFR §§ 3.307(a)(7) and 3.309(f) (Camp Lejeune presumptive list, which does not include prostate cancer), 38 CFR §§ 3.309(d) and 3.311 (radiation claims), 38 USC § 1114(k) and 38 CFR § 3.350 (Special Monthly Compensation), all checked against the current text on October 6, 2026, and Claim Raven's read of every Board decision from 2021 to 2026 that it holds: 511,036 decisions containing 1,378,030 rulings. Treatment side effects are from Pignot et al., "Self-reported functional assessment after treatment for prostate cancer: 5-year results of the prospective cohort VICAN," Future Oncology (2022), and Nguyen et al., "Patient Reported Outcomes and Treatment-Associated Complications as a Consideration in Selecting Localized Prostate Cancer Management," Research and Reports in Urology (2025), read as PubMed abstracts.
• Sample size: 8,183 Board rulings on prostate cancer, 7,485 of them decided. Of the decided rulings, 2,417 were granted (32.3%), 2,311 denied (30.9%) and 2,757 remanded (36.8%). Claim theory, medical opinion, appeal type, and denial and remand reason figures appear in the Board section below, computed from the same data. Claim theory counts decided service connection rulings, remands included. Medical opinion tiers count only service connection rulings the Board granted or denied, because remands are not read for that question. The read does not code assigned rating tiers.
• Limitations: The read captures Board-level decisions. Claims granted at the regional office without appeal aren't in it. The Agent Orange presumptive framework has been amended several times and the qualifying-service definitions have expanded; older BVA decisions in the dataset may reflect superseded versions. SMC-K eligibility is a separate analysis from the DC 7528 rating and the dataset doesn't reliably track SMC-K assertion or grant. Residuals ratings post-treatment depend heavily on the specific symptoms documented in each case. The figures here are associations, not causes. These observations describe BVA patterns and are not predictions of individual outcomes, and Claim Raven is data analysis, not legal, medical, or VA-accredited advice.